Retinoic acid receptors are members of the nuclear receptor super family, which act as ligand-regulated *trans*-acting transcription factors that bind to *cis*-acting DNA regulatory elements in the promoter regions of target genes. Three RAR subtypes (RAR*α*, RAR*β*, and RAR*γ*) originating from three distinct genes have been identified ([Mangelsdorf *et al*, 1990](#bib24){ref-type="other"}; [Gronemeyer *et al*, 2004](#bib13){ref-type="other"}). RARs belong to the steroid/thyroid hormone receptor super-family, which share a common domain structure, denoted A-F. The C region contains the DNA-binding domain, which is most conserved among the different members of this family and consists of two zinc fingers. The hormone-binding domain is located in the E region and contains, besides the binding domain, a dimerisation domain and a hormone-dependent transactivation function (AF-2). The N-terminal part of the receptor (AB) also contains an autonomous region involved in transactivation (AF-1), which functions independently from the ligand, when coupled with a heterologous DNA-binding domain. As the NH~2~-terminus is not conserved among different receptors, they each may achieve this function by distinct means ([Evans, 1988](#bib11){ref-type="other"}; [Leid *et al*, 1992](#bib18){ref-type="other"}).

Of particular interest is the RAR*β*~2~ subtype, which regulates essential pathways associated with the anti-tumour effects of retinoids in epithelial cells. The RAR*β*~2~ gene promoter contains a retinoic acid response element (RARE) to which the liganded RAR*α*/RXR*α* heterodimer binds to induce RAR*β*~2~ expression ([Alvarez *et al*, 2007](#bib1){ref-type="other"}). The expression of RAR*β*~2~ is frequently reduced in many neoplastic tissues when compared with their normal cellular counterparts, including non-small cell lung cancer, squamous cell carcinomas of the head and neck, breast cancer and neuroblastoma ([Cheung *et al*, 1996](#bib7){ref-type="other"}; [Castillo *et al*, 1997](#bib5){ref-type="other"}; [Picard *et al*, 1999](#bib27){ref-type="other"}). The reactivation of silenced RAR*β*~2~ upon induction of RAR*α* expression and concomitant retinoic acid treatment was associated with a clinical response of oral leukoplakia ([Lotan *et al*, 1995](#bib22){ref-type="other"}). In a clinical study where renal carcinoma patients were treated with 13-*cis*-retinoic acid and interferon-*α*, the levels of RAR*β*~2~ increased in tumours that clinically responded to therapy ([Berg *et al*, 1999](#bib3){ref-type="other"}).

Copper plays an essential role in human physiology and is indispensable for normal growth and development. Enzymes that are involved in connective tissue formation, neurotransmitter biosynthesis, iron transport and other essential physiological processes require copper as a cofactor to mediate their reactions. The transport and cellular metabolism of copper depends on a series of membrane proteins and smaller soluble peptides that comprise a functionally integrated system for maintaining cellular copper homeostasis. Two membrane-bound copper-transporting ATPase enzymes, ATP7A and ATP7B, can catalyse an ATP-dependent transfer of copper to intracellular compartments or expel copper from the cell ([Harris, 2000](#bib15){ref-type="other"}; [El Meskini *et al*, 2005](#bib9){ref-type="other"}), respectively. A truncated splice variant of ATP7A, termed NML45 (Nuclear Menkes Like) has also been described that encodes a theoretical 11.2-kDa protein with one copper-binding site, and may function as a nuclear copper chaperone ([Reddy *et al*, 2000](#bib28){ref-type="other"}).

We have previously identified the copper metabolism gene ATP7A as a retinoid-regulated gene in neuroblastoma cell lines ([Liu *et al*, 2005](#bib20){ref-type="other"}). In non-neuronal cells, ATP7A is responsive to levels of intracellular copper, and is predominantly localised to the *trans*-Golgi network when cytosolic copper levels are normal or low. In the presence of excess copper, ATP7A functions in copper excretion and a distinct pool of ATP7A is relocated to the plasma membrane through cytoplasmic vesicles. It is rapidly recycled, returning to the *trans*-Golgi network once cytoplasmic copper levels are normal ([La Fontaine *et al*, 1999](#bib17){ref-type="other"}; [Lutsenko and Petris, 2003](#bib23){ref-type="other"}). In neurons ATP7A is developmentally regulated, being initially expressed in cell bodies of developing neurons, with later expression shifting to the extending axons and peaking just prior to synaptogenesis ([El Meskini *et al*, 2005](#bib9){ref-type="other"}). ATP7A has an important function in neurodevelopment, and is involved in axonal targeting, synaptogenesis and maturation of olfactory sensory neurons ([El Meskini *et al*, 2007](#bib10){ref-type="other"}).

In this study, we investigated the mechanisms of RAR*β*~2~ in mediating ligand-dependent and ligand-independent growth inhibition functions by using *in vitro* models. Our results show a previously unrecognised relationship between the RAR*β*~2~ and the anticancer effects of retinoids with ATP7A and intracellular copper levels.

Materials and methods
=====================

Cell culture
------------

The human neuroblastoma BE(2)-C and SH-SY5Y cell lines were generously supplied by Dr J Biedler (Memorial Sloan-Kettering Cancer Centre, NY, New York, USA). The human lung cancer H441 and SK-MES-1, human breast cancer MDA-MB-468, MDA-MB-231 and MCF7, and skin immortal keratinocyte HEK001 cells were obtained from the American Type Culture Collection (Manassas, VA, USA). The HEK001 was cultured in a specific keratinocyte serum-free media as specified by the ATCC. All other cells were cultured in Dulbecco\'s modified Eagle\'s medium supplemented with [L]{.smallcaps}-glutamine and 10% fetal calf serum. *All-trans*-retinoic acid (aRA) was purchased from Sigma (NSW, Australia), was solubilised in ethanol, stored at −70°C, and used within 2 weeks of solubilisation. Triethylenetetramine (TETA), a selective copper chelator, was also purchased from Sigma.

Semi-quantitative competitive reverse transcriptase--polymerase chain reaction
------------------------------------------------------------------------------

The competitive RT--PCR techniques have been described earlier ([Norris *et al*, 1997](#bib26){ref-type="other"}; [Cheung *et al*, 2003](#bib8){ref-type="other"}), which involved determining a ratio between the level of expression of a target gene and that of the housekeeping gene *β*~2~-microglobulin (*β*~2~M) in total RNA samples. Primers used for RT--PCR assays are as follows: human ATP7A forward: 5′-GGAATTCCCATAGCTGCTGG-3′; human ATP7A reverse: 5′GTAAGTTGGTTTCCTGTAAA-3′. This primer pair generated a 140-bp product extending from 4233 to 4373 bp of published ATP7A sequence. NLM45 forward: 5′-CTGAGCATCAGAAAGAGACCA-3′; NML45 reverse: 5′-ATCTGCTGCTCAATGGTCCA-3′. This primer pair generated a 146-bp product extending from 122 to 146 bp of published NML45 sequence. Human RAR*β*~2~ forward: 5′-CTACACTGCGAGTCCGTCTT-3′. Human RAR*β*~2~ reverse: 5′-CAGAGCTGGTGCTCTGTGTT-3′. This primer pair generated a 131-bp product extending from 375 to 506 bp of published RAR*β*~2~ sequence.

Quantitative real-time PCR
--------------------------

cDNA for real-time PCR was synthesized from total RNA using a Superscript III synthesis kit and Oligo(dT)~20~ primer (Invitrogen, Vic, Australia), according to manufacturer instructions. The cDNA (40 ng) was amplified in 25 *μ*l reactions using a Power SYBR Green PCR master mix (Applied Biosystems, Melbourne, VIC, Australia) and 100 ng each of forward and reverse primers on an ABI PRISM 7500 Sequence Detection System (Applied Biosystems). The cycle threshold (*C*~t~), fixed in the exponential phase of the PCR, was used to determine gene expression relative to a calibrator. For each sample, the *C*~t~ value of the target gene was normalised to the endogenous control gene *β*~2~M. Relative gene expression was calculated with the 2^−ΔΔ*C*~t~^ method ([Livak and Schmittgen, 2001](#bib21){ref-type="other"}). Real-time PCR primer sequences are listed as follows: Human ATP7A forward: 5′-TGGCAAGGCAGAAGTAAGGTATAA-3′; Human ATP7A Reverse: 5′-ACGTCATTCCCCTCACAACAAG-3′; Human RAR*β*~2~ forward: 5′-TGAAAATCACAGATCTCCGTAGCA-3′; Human RAR*β*~2~ reverse: 5′-CCAGGAATTTCCATTTTCAAGGT-3′; Human *β*~2~M forward: 5′ACTGGTCTTTCTATCTCTTGTACTACACTGA-3′; Human *β*~2~M reverse: 5′ TGATGCTGCTTACATGTCTCGAT-3′.

Plasmid construction
--------------------

The full-length human cDNA for RAR*β*~2~ (kindly provided by Professor P Chambon, INSERM, Strasbourg, France) was cloned into the *Pvu*II multi-cloning site of the pMEP4 episomal Epstein--Barr virus-based expression vector (kindly provided by Dr M Tykocinski, Case Western University, Cleveland, OH, USA) ([Cheung *et al*, 1996](#bib7){ref-type="other"}). We designed mutant RAR*β*~2~ cDNAs, which were deleted for either the ligand-independent AF-1 transactivating domain (A-B) and the DNA-binding domain (C) -- ΔDEF, or the ligand-binding domain (E-F) -- ΔABC and ΔAB ([Figure 1B](#fig1){ref-type="fig"}). We used a PCR-based strategy to amplify separate regions of the RAR*β* cDNA by using pREP/RAR*β* plasmid DNA as template ([Cheung *et al*, 1996](#bib7){ref-type="other"}). The mutant RAR*β* cDNAs were subcloned into the multi-cloning site (*Hind III* and *Cla I*) of a pTet-splice Myc/His vector (Invitrogen). Plasmid pTet-tTAK (Invitrogen) was stably transfected into BE(2)-C cells to establish stable BE(2)-C pTet-tTAK clones. The pTet-splice vectors which contained the RAR*β* mutants were transiently transfected into BE(2)-C (pTet-tTAK clones) and BrdU incorporation was performed in medium without tetracycline.

The oligonucleotides used for the PCR assay of RAR*β* deletion mutants were as follows: Forward primer for ΔDEF: 5′-AGTCGAGGTATCGATGTTTGACTGTATGGATGT-3′; Reverse primer for ΔDEF: 5′-AGCAGAAAGCTTGGACATTCCCACTTCAAAGC-3′; Forward primer for ΔAB: 5′-AGTCGAGGTATCGATGGCTTCGTCTGCCA-3′; Forward primer for ΔABC: 5′-AGTCGAGGTATCGATGAAAGAATCTGTCAGGAA-3′; Reverse primer for both ΔAB and ΔABC: 5′-AGCAGAAAGCTTAAGGGTTCATGTCCTTCAGA-3′.

Assays of neurite formation and viability assays
------------------------------------------------

Neurite extension of neuroblastoma cells BE(2)-C was determined after 7 days of continuous exposure to 10 *μ*[M]{.smallcaps} aRA and 30 or 100 *μ*[M]{.smallcaps} copper. Cells were scored as positive for neurite outgrowth if the neuritic process was longer than the cell body. The percentage of positive cells was counted within each high-powered field, with a total of 300 cells counted in an average of five fields. Each experiment was performed in duplicate on three separate occasions. Cell viability was assessed using Alamar Blue reagent as described earlier ([Haber *et al*, 1999](#bib14){ref-type="other"}).

siRNA-transient transfection
----------------------------

SH-SY5Y and BE(2)-C cells at approximately 50% confluence were transfected with 30 n[M]{.smallcaps} ATP7A siRNA (Smart Pool: Dharmacon, Chicago, IL, USA) or 10 n[M]{.smallcaps} RAR*β*~2~ siRNA and 10 n[M]{.smallcaps} siGENOME non-targeting siRNA as control siRNA (Dharmacon) using Lipofectamine 2000 (Invitrogen) reagent according to the manufacturer\'s protocols. Following transfection, cells were incubated overnight in normal media, and then treated with 1 *μ*[M]{.smallcaps} aRA or solvent control. Cells were harvested and RNA was extracted 48 or 72 h later. Transfection efficiency and its effect on target gene expression, was assessed by competitive RT--PCR.

Western blot
------------

Cells were harvested in the presence of protease inhibitors by direct lyses in the culture vessel with lyses buffer (RIPA: 100 m[M]{.smallcaps} NaCl, 0.5% Sodium deoxycholate, 50 m[M]{.smallcaps} Tris-Cl, 0.1% SDS, 1% NP-40) and then transferred to eppendorf tubes. Soluble proteins were analysed by SDS--PAGE as published earlier ([Cheung *et al*, 2003](#bib8){ref-type="other"}). Membranes were probed with chicken IgY anti-ATP7A which is specific for full-length ATP7A (no. ab13995: Abcam, Cambridge, UK), at a dilution of 1/1000 overnight at 4°C. Membranes were then incubated for 1 h at room temperature with a secondary antibody, HRP conjugated rabbit anti-chicken (no. ab6753: Abcam) at a dilution of 1/2000. Membranes were re-probed with an anti-*β*-Actin antibody (Pierce, IL, USA) as a loading control, according to methods described earlier ([Cheung *et al*, 2003](#bib8){ref-type="other"}). Relative protein expression was determined by standardising target protein bands against *β*-Actin using ImageQuant software (Amersham, NSW, Australia).

Mouse monoclonal antibody anti-Myc-Tag (9B11) was purchased from Cell Signalling Technology Inc. (MA, USA) for detecting RAR*β*~2~ full-length and its mutant\'s expression in BE(2)-C cells. Anti-Myc-Tag antibody for RAR*β*~2~ deletion mutants immunoblot was used at a 1 : 1000 dilution in 0.5% defatted milk in a TBST buffer. Rabbit polyclonal Actin antibody (Sigma, St Louis, MO, USA) was used at a 1 : 2000 dilution to normalise for differences in loading. Subsequently, membranes were incubated with horseradish peroxidise, anti-mouse or anti-rabbit secondary antibody (Pierce Biotechnology Inc., IL, USA), which was used at a 1 : 5000 dilution. Chemiluminescent detection was performed using the SuperSignal western blotting kit (Pierce Biotechnology, Rockford, IL, USA), according to the manufacturer\'s instructions.

Accumulation of copper 64
-------------------------

The accumulation of radioactive copper was analysed using standard techniques ([Richardson and Baker, 1990](#bib29){ref-type="other"}; [Arredondo *et al*, 2006](#bib2){ref-type="other"}). Briefly, BE(2)-C and SH-SY5Y cells in 35 mm wells were incubated for 2 h at 37°C with 10 *μ*Ci ml^−1^ ^64^Cu, in the form of CuCl~2~ (ARI, Lucas Heights, NSW, Australia) in DMEM supplemented with 10% fetal calf serum. The cells were then placed on a tray of ice and washed four times with ice-cold PBS to remove any non-specifically bound ^64^Cu. The internalised and membrane-bound ^64^Cu were incubated with 1 ml trypsin. After this incubation, the cells were then removed from the wells and transferred to *γ*-counting tubes. Radioactivity was measured using a *γ*-counter (Wallac Wizard 3; Turku, Finland). Control experiments in previous investigations have found that this technique is valid for measuring membrane-bound and internalised radioactivity ([Karin and Mintz, 1981](#bib16){ref-type="other"}).

Efflux of copper 64
-------------------

The release of ^64^Cu by pre-labelled cells was examined using standard procedures ([Richardson and Baker, 1991](#bib30){ref-type="other"}; [Food *et al*, 2002](#bib12){ref-type="other"}). Cells in 35 mm wells were labelled with 10 *μ*Ci ml^−1^ ^64^Cu in DMEM containing 10% fetal calf serum for 2 h at 37°C. The 35 mm plates were subsequently placed on a tray of ice and washed four times with ice-cold PBS. The cells were then re-incubated with warm DMEM for incubation periods from 1, 2.5 or 4 h to allow cells to efflux copper into the medium. The overlying medium was then removed and placed into *γ*-counting tubes. The cells were removed from the 35 mm well plates, either by trypsinisation or direct lyses, and transferred to a separate set of *γ*-counting tubes. Total ^64^Cu accumulated by cells prior to efflux was determined for each well by adding CPM for ^64^Cu effluxed and ^64^Cu retained in the cells. ^64^Cu effluxed was expressed as a percentage of total ^64^Cu accumulated. Estimates of ^64^Cu accumulated per cell was obtained by standardising total ^64^Cu accumulated against estimated cell viability (OD).

Results
=======

Growth and tumour-suppressive activity of RAR*β*~2~ in neuroblastoma cells
--------------------------------------------------------------------------

We first determined the effect of RAR*β*~2~ expression on the proliferative capacity of neuroblastoma cells in the presence and absence of 10 *μ*[M]{.smallcaps} all-*trans*-retinoic acid (aRA). We performed a BrdU incorporation assay in two human neuroblastoma cell lines (BE(2)-C and SH-SY5Y) transiently transfected with a siRNA specific for RAR*β*~2~, followed by 48 h of aRA treatment. RAR*β*~2~ expression was reduced by 60% when compared to control siRNA as measured by gel densitometry in both cell lines ([Figure 1A](#fig1){ref-type="fig"}). Cell proliferation was significantly increased, with or without aRA, in both neuroblastoma cell lines following RAR*β*~2~ knockdown, compared with cells transfected with a non-specific siRNA control ([Figure 1A](#fig1){ref-type="fig"}).

To understand the relationship between RAR*β*~2~ protein structure and its effects on cell proliferation in the absence of additional retinoid, we made a series of RAR*β*~2~ deletion mutants in a tetracycline-inducible expression (Tet-off) vector with a Myc oligopeptide tag ([Figure 1B](#fig1){ref-type="fig"}). The RAR*β*~2~ deletion mutant proteins were transiently expressed in BE(2)-C cells, and, an anti-Myc epitope antibody identified the expression of all mutant proteins expected. Cell proliferation was measured by BrdU incorporation after cells were grown in culture medium without doxycycline for 72 h. Overexpression of the full length RAR*β*~2~ resulted in significantly decreased cell proliferation compared with empty vector. Most importantly, overexpression of the ABC domain (ΔDEF) of the RAR*β*~2~ protein alone was sufficient for the growth inhibitory effects of RAR*β*~2~ in BE(2)-C cells. In contrast, overexpression of CDEF (ΔAB) and DEF (ΔABC) domains of RAR*β*~2~ did not decrease cell proliferation ([Figure 1C](#fig1){ref-type="fig"}).

RAR*β* regulates the expression of ATP7A in neuroblastoma cells
---------------------------------------------------------------

We have previously identified the copper efflux pump protein, ATP7A, as a retinoid-regulated gene using a cDNA microarray analysis of retinoid-treated neuroblastoma cells ([Liu *et al*, 2005](#bib20){ref-type="other"}). Here, we examined the hypotheses that RAR*β*~2~ may regulate ATP7A, and, that ATP7A may be responsible for the growth suppressive effects of RAR*β*~2~ in neuroblastoma cells. We found that transcription of both the full-length ATP7A, and the ATP7A splice variant, NML45, were markedly induced by aRA in BE(2)-C and SH-SY5Y cells after treatment with 10 *μ*[M]{.smallcaps} aRA for 7 days ([Figure 2A](#fig2){ref-type="fig"}). Consistent with these findings, ATP7A protein expression was also induced by aRA after 3 days of treatment ([Figure 2B](#fig2){ref-type="fig"}). Retinoid-induced upregulation of ATP7A appeared to be specific for neuroblastoma cells, as we could not demonstrate an increase in ATP7A mRNA expression in skin, lung or breast cancer cells following retinoid treatment ([Figure 2C](#fig2){ref-type="fig"}). We have also observed that the aRA decreases ATP7A mRNA expression in oestrogen-receptor positive MCF7 cells, but not in MDA-MB-234 and MDA-MB-468 breast cancer cells.

We have previously characterised two clonally-derived BE(2)-C cell lines stably overexpressing RAR*β*~2~, which exhibited growth suppression in the absence of added retinoid ([Cheung *et al*, 1998](#bib6){ref-type="other"}). Both RAR*β*~2~ clones demonstrated increased ATP7A and NML45 expression, when compared with empty vector transfectants. Interestingly, the levels of the splice variant NML45 does not correlate with the levels of RAR*β*~2~ in two different RAR*β*~2~ clones ([Figure 3A](#fig3){ref-type="fig"}). We next transiently transfected BE(2)-C cells with RAR*β*~2~-specific siRNA, treated the cells with 10 *μ*[M]{.smallcaps} aRA for 48 h, and examined RAR*β*~2~ and ATP7A expression. Consistent with our previous findings, expression of retinoid-induced RAR*β*~2~ and ATP7A was coordinately decreased, compared with retinoid-untreated samples ([Figure 3B](#fig3){ref-type="fig"}). Additionally, transiently expressing the RAR*β*~2~ full-length and the ΔDEF deletion mutant, significantly increased ATP7A expression ([Figure 3B](#fig3){ref-type="fig"}). Thus, we found a close relationship between RAR*β*~2~ and ATP7A expression levels, and growth inhibition in several different model systems, supporting the notion that ATP7A may mediate the retinoid ligand-dependent, and -independent, actions of RAR*β*~2~.

The retinoid anti-cancer effect is mediated by effects on ATP7A and intracellular copper
----------------------------------------------------------------------------------------

We next examined the hypothesis that ATP7A mediates the effects of RAR*β*~2~ on neuroblastoma cells by its effects on intracellular copper metabolism. We measured copper efflux in neuroblastoma cells (BE(2)-C and SH-SY5Y) which were pre-treated with 10 *μ*[M]{.smallcaps} aRA over a time course of 8 days, then loaded with radioactive ^64^Cu. After ^64^Cu loading, cells were washed, then incubated in normal growth media to allow copper efflux over a short 4 h time course. In both cell lines there was a higher copper efflux in cells pre-treated with aRA at 4 h ([Figure 4A](#fig4){ref-type="fig"}). As the retinoid treatment affects the cell number at the end of the growth period, ^64^Cu uptake was standardised against cell viability, as assessed by the Alamar Blue assay ([Figure 4B](#fig4){ref-type="fig"}). Retinoid treatment resulted in a marked decrease in ^64^Cu accumulation in both SH-SY5Y and BE(2)-C cells.

To directly examine the role of ATP7A in modulating copper efflux in neuroblastoma cells, we used siRNA specific for ATP7A. Transient transfection of SH-SY5Y cells with an ATP7A siRNA lead to a 36% +/− 0.018 s.e.m. reduction in ATP7A expression and a 27% +/− 0.015 s.e.m. reduction in the rate of copper efflux in retinoid-untreated cells, suggesting that the rate of copper efflux in this cell line was dependent on ATP7A, and, was proportional to the level of ATP7A expression ([Figure 4C](#fig4){ref-type="fig"}). There was no effect on BE(2)-C cells. The ATP7A knock-down did not alter the copper accumulation in untreated SH-SY5Y or BE(2)-C cells. We next examined the effect of inhibiting ATP7A expression on the viability of retinoid-treated neuroblastoma cells. Owing to the combined toxicity of siRNA and retinoid treatment, the experiment was limited to 24 h retinoid treatment, and a lower retinoid concentration of 1 *μ*[M]{.smallcaps} aRA. In both SH-SY5Y and BE(2)-C cells, a reduction in ATP7A expression of approximately 30% correlated with an increase in cell viability in the Alamar Blue assay, compared with a non-specific siRNA control ([Figure 4D](#fig4){ref-type="fig"}).

We next examined the effects of copper supplementation on the retinoid responses of neuroblastoma cells. BE(2)-C and SH-SY5Y cells were grown according to standard techniques, in the absence of added retinoid and supplemented with 0, 30, 100 and 300 *μ*[M]{.smallcaps} copper treatment for 48 h. Cell proliferation was assessed using the BrdU incorporation assay. Supplementing BE(2)-C with 30, 100 and 300 *μ*[M]{.smallcaps} CuCl~2~ significantly increased cell proliferation ([Figure 5A](#fig5){ref-type="fig"}). None of the concentrations tested increased the proliferation of SH-SY5Y cells (data not shown). BE(2)-C and SH-SY5Y cells were then grown for 7 days with 10 *μ*[M]{.smallcaps} aRA, in the presence or absence of 30 and 100 *μ*[M]{.smallcaps} CuCl~2~. After 7 days, differentiation was assessed by neurite count. Added CuCl~2~ significantly reduced neurite formation in BE(2)-C cells over the 7 day retinoid treatment ([Figure 5A](#fig5){ref-type="fig"}). Moreover, the copper chelator, Triethylenetetramine (TETA), reduced the viability and proliferative capacity of BE(2)-C cells compared to cells grown without TETA. The effect was completely abrogated when TETA was added with equimolar CuCL~2~ ([Figure 5B](#fig5){ref-type="fig"}). Copper supplementation had no observable effect on retinoid-induced differentiation of SH-SY5Y cells. In both cell lines copper supplementation did not affect the neurite count of cells grown in the absence of the added retinoid (data not shown).

Lastly, we investigated whether a combination of retinoid and copper chelator could increase their anti-cancer activity. Both BE(2)-C and SH-SY5Y neuroblastoma cells were treated with a single agent or a combination of aRA (1 *μ*[M]{.smallcaps}) and TETA (60 *μ*[M]{.smallcaps}) for 72 h. The effect of the copper chelator by itself had only a minor growth inhibitory effect on SH-SY5Y and BE(2)-C cell lines, whereas the combination treatment of retinoid and copper chelator had a marked effect on cell viability and proliferation ([Figure 6](#fig6){ref-type="fig"}).

Discussion
==========

A therapeutic role for retinoids in several human cancer types, including neuroblastoma, is well established. However, retinoids are not completely effective anti-cancer agents when used alone; thus, a better understanding of their mechanism of action will lead to more evidence-based retinoid combination therapies. In this study we have demonstrated that RAR*β*~2~ has a strong, retinoid-dependent and -independent, anti-proliferative effects on neuroblastoma cells. Furthermore, we have, for the first time, identified a link between the retinoid anti-cancer signal and intracellular copper levels, which has important implications for the understanding of the tumorigenic process and therapy of neuroblastoma.

In human neuroblastoma cells, knocking down RAR*β*~2~ expression resulted in a clear increase in cell proliferation, regardless of whether or not exogenous retinoid was added. Conversely, overexpression of RAR*β* resulted in a strong decrease in cell proliferation. The RAR*β*~2~ anti-proliferative effect required only the ABC domain (AF1 and DNA-binding domains), and not the retinoid-binding domain or receptor dimerisation interface. This result strongly suggests that RAR*β*~2~ has both retinoid-dependent and -independent anti-cancer functions.

In a previous study using the cDNA microarray, we found that the copper transporter ATP7A was strongly upregulated in neuroblastoma cells in response to retinoid ([Liu *et al*, 2005](#bib20){ref-type="other"}). In this study, we found that ATP7A protein expression is upregulated in neuroblastoma cells after retinoid treatment. As retinoid treatment did not result in similar upregulation of ATP7A expression in the non-neuronal cell lines, which tested, we suggest that retinoid regulation of ATP7A is tissue type-dependent and may be specific to neuronal cells. We have also shown that ATP7A upregulation can be achieved by ectopic expression of full-length RAR*β*~2~ or the RAR*β*~2~ ABC domain in the absence of added retinoid. Our data supports the notion that RAR*β*~2~, directly or indirectly regulates ATP7A expression in a retinoid-dependent and -independent manner.

During neuronal development, ATP7A expression over time is precisely regulated, and varies according to cell type ([Linz and Lutsenko, 2007](#bib19){ref-type="other"}). Studies of the mouse brain show that ATP7A expression is most abundant in the early postnatal period and decreases from birth to adulthood ([Niciu *et al*, 2006](#bib25){ref-type="other"}). The mechanism by which RAR*β* regulates ATP7A expression is unknown. As there are no known RARE in the ATP7A promoter region, it is likely that RAR*β* regulates ATP7A expression level indirectly. Previous studies focused on the role of ATP7A in Menke\'s disease, have shown that ATP7A expression and copper plays an important role in neural differentiation and neuritogenesis ([El Meskini *et al*, 2005](#bib9){ref-type="other"}, [2007](#bib10){ref-type="other"}; [Birkaya and Aletta, 2005](#bib4){ref-type="other"}). We found an increase in cell viability when ATP7A expression was knocked down in neuroblastoma cells ([Liu *et al*, 2005](#bib20){ref-type="other"}). The significant correlation between ATP7A and RAR*β* expression suggests that ATP7A may contribute to the RAR*β* anti-cancer therapeutic effect.

The role of copper in biological phenomena that involve signal transduction is poorly understood. A cellular model of neuronal differentiation has been utilised to examine the requirement for copper during nerve growth factor (NGF) signal transduction that leads to neurite outgrowth ([Birkaya and Aletta, 2005](#bib4){ref-type="other"}). NGF increases cellular copper content within 3 days, whereas copper chelators reduce the effects of NGF on neurite outgrowth and copper accumulation ([Birkaya and Aletta, 2005](#bib4){ref-type="other"}). Our data supports a model of malignant neural cells requiring higher intracellular copper levels for viability, and that retinoid-induced neuritic differentiation of neuroblastoma cells causes intracellular copper depletion. In non-neuronal cells ATP7A regulates copper homeostasis by translocating copper from the *trans*-Golgi network to the plasma membrane, in response to an increased copper load. In Menkes disease a defect in the ATP7A protein leads to a reduced transport of copper from the intestine into the circulation and central nervous system, as well as reduced transport of copper into the Golgi apparatus. In our studies, a significant increase in copper efflux, and decrease in copper uptake occurred over 8 days of retinoid treatment. Thus, reduction in cellular copper levels directly contributes to the retinoid therapeutic effect.

In summary, our results indicate that ATP7A is an important component of the RAR*β* anticancer effect. Most importantly, copper chelators reduce viability and proliferation of neuroblastoma cells. ATP7A and copper are novel potential drug targets that may be exploited in the treatment of neuroblastoma.
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![Tumour-suppressive activity of RAR*β*~2~ in neuroblastoma tumour cells. (**A**) BE(2)-C and SH-SY5Y cells were transfected with control siRNA or RAR*β*~2~-specific siRNA, followed by treatment with 10 *μ*[M]{.smallcaps} aRA for 48 h and incubation with BrdU for the last 2 h. In the upper panel, BrdU incorporation was measured as OD units of absorbance. In the lower panel, RT--PCR experiments show the knock-down of RAR*β*~2~ mRNA expression level by RAR*β*~2~-specific siRNA. (**B**) Schematic representations of RAR*β*~2~ full-length and deletion mutant constructs used in this study. In the right panel, expression of RAR*β*~2~ full length and deletion mutants in BE(2)-C pTet-tTAK cells were analysed by western blot by using anti-Myc-tag antibody. The lysates of the cells transiently transfected with empty vector (EV, lane 1), RAR*β*~2~ full-length (lane 2, 50 KDa), ΔDEF (lane 3, 16 kDa), ΔABC (lane 4, 34 kDa) and ΔAB (lane 5, 41 kDa) constructs were used in this study. (**C**) Proliferation of BE-tet-75 cells transiently transfected with RAR*β*~2~ full-length and deletion mutant constructs in the absence of added retinoid. ^\*^*P*\<0.05 and ^\*\*^*P*\<0.01 indicate a statistically significant difference compared with untreated control ([Figure 1A](#fig1){ref-type="fig"}) or empty vector control ([Figure 1C](#fig1){ref-type="fig"}). Error bars indicate s.e.m.](6604833f1){#fig1}

![ATP7A is induced by retinoid in neuroblastoma tumour cells. (**A**) Competitive RT--PCR analysis of cDNA samples from cultured neuroblastoma cells treated with 10 *μ*[M]{.smallcaps} aRA, or a solvent control, for up to 7 days. Abundance of ATP7A transcripts (full length and NML45) present in SH-SY5Y and BE(2)-C cDNA samples relative to *β*~2~M neuroblastoma cell lines. (**B**) Western blot analysis of ATP7A protein expression from cultured neuroblastoma cells treated with 10 *μ*[M]{.smallcaps} aRA, or a solvent control, for up to 7 days. Actin gene was used as a loading control. (**C**) Competitive RT--PCR analysis of ATP7A mRNA expression in cDNA samples from cultured cancer cells treated for 7 days with 10 *μ*[M]{.smallcaps} aRA, or a solvent control.](6604833f2){#fig2}

![ATP7A transcription is modulated by RAR*β*~2~ in neuroblastoma cells. (**A**) RT--PCR analysis of RAR*β*~2~, full length ATP7A and the NML45 ATP7A mRNA expression in RAR*β*~2~ stably transfected BE(2)-C cells, compared to empty vector transfected control cells, (**B**) In the left panel, Real-time PCR analysis of RAR*β*~2~ and ATP7A mRNA expression were measured, after 72 h siRNA transfection in BE(2)-C cells with or without 10 *μ*[M]{.smallcaps} aRA treatment for 48 h. Target gene expression was normalised to the expression of the housekeeping gene *β*~2~M. In the right panel, RT--PCR analysis of ATP7A mRNA expression in the full length RAR*β*~2~ and the RAR*β*~2~ ΔDEF deletion mutant, compared with empty vector transfected BE(2)-C cells. ^\*^*P*\<0.05 and ^\*\*^*P*\<0.005 indicate a statistically significant difference compared with control. Error bars indicate s.e.m.](6604833f3){#fig3}

![Modulation of cellular copper efflux and accumulation by retinoid treatment in neuroblastoma cells. (**A**) Copper efflux was monitored over 4 h, and is expressed as a percentage of copper uptake in both SH-SY5Y and BE(2)-C cells after 10 *μ*[M]{.smallcaps} aRA treatment for 8 days. (**B**) SH-SY5Y and BE(2)-C cells were treated for 2, 4 and 8 days with 10 *μ*[M]{.smallcaps} aRA, or with a control treatment, and viability measured using Alamar Blue assay. Cells were then incubated in normal media with 10 *μ*C radioactive ^64^Cu for 2 h to allow uptake. ^64^Cu accumulation is expressed as counts per minute, standardised against cell viability. (**C**) SH-SY5Y cells were transient transfected with an ATP7A siRNA without aRA treatment. ATP7A mRNA expression were measured by RT--PCR. The rate of copper efflux in SH-SY5Y was measured as described in Materials and methods section. (**D**) BE(2)-C and SH-SY5Y cells were treated with 1 *μ*[M]{.smallcaps} aRA treatment for 24 h, knock-down of ATP7A expression by ATP7A siRNA (left panel) resulted in an increase in cell viability as measured by the Alamar Blue assay (right panel).](6604833f4){#fig4}

![Effect of copper supplementation and depletion in neuroblastoma cells. (**A**) In the left panel, supplementing with up to 300 *μ*[M]{.smallcaps} CuCl~2~, over 48 h growth, caused an increase in proliferation of BE(2)-C cells measured by Brdu incorporation. In the right panel, BE(2)-C cells were grown for 7 days with 10 *μ*[M]{.smallcaps} aRA, in the presence or absence of CuCl~2~. At the end of 7 days, differentiation was assessed by neurite count. (**B**) Depletion of available copper from the media by addition of the copper chelator Triethylenetetramine (TETA) at 30 or 60 *μ*[M]{.smallcaps} (final concentration) caused a decrease in viability of BE(2)-C cells as measured by Alamar Blue assay. The 60 *μ*[M]{.smallcaps} TETA also resulted in decreased proliferation of BE(2)-C cells as measured by the BrdU assay. Neutralisation of TETA by addition of equimolar CuCl~2~ abrogated its effects. ^\*^*P*\<0.05 indicate a statistically significant difference compared with untreated.](6604833f5){#fig5}

![Growth inhibitory effects of combined copper chelator and retinoid treatment. BE(2)-C and SH-SY5Y cells were treated by 1 *μ*[M]{.smallcaps} aRA, 60 *μ*[M]{.smallcaps} TETA or combination of 1 *μ*[M]{.smallcaps} aRA and 60 *μ*[M]{.smallcaps} TETA for 72 h, cell growth was measured by BrdU incorporation and Alamar Blue assay. ^\*^*P*\<0.05 and ^\*\*^*P*\<0.005 indicate a statistically significant difference compared with control.](6604833f6){#fig6}
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